Moderna exits Metagenomi gene editing deal worth $3B biobucks Fierce BiotechModerna breaks off deal with CRISPR company Metagenomi STATMetagenomi to regain full development rights to its wholly-owned base editing and RIGS systems GlobeNewswire
Read More…